| P2093 | author name string | Baskaran Thyagarajan | |
| | Jonathan H Fox | |
| | Sonal Agrawal | |
| | Julia Fox | |
| P2860 | cites work | The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice | Q24656405 |
| | Iron Homeostasis in Health and Disease | Q26775146 |
| | Huntington's disease: underlying molecular mechanisms and emerging concepts | Q27026255 |
| | A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 |
| | Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer beta-amyloid pathology | Q48599293 |
| | Requirement for superoxide in excitotoxic cell death | Q49133494 |
| | Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis? | Q49490050 |
| | Assay for lipid peroxide content in mitochondria by the thiobarbituric acid reaction | Q69428258 |
| | Measurement of iron and copper in biological systems: bleomycin and copper-phenanthroline assays | Q71630063 |
| | Induction of the mitochondrial permeability transition (MPT) by micromolar iron: liberation of calcium is more important than NAD(P)H oxidation | Q84225449 |
| | The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease | Q28072937 |
| | Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes | Q28386769 |
| | Inhibition of mitochondrial protein import by mutant huntingtin | Q28394803 |
| | Oxygen consumption deficit in Huntington disease mouse brain under metabolic stress | Q28397230 |
| | Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's Disease | Q28512442 |
| | Mitoferrin is essential for erythroid iron assimilation | Q28587125 |
| | Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators | Q29617353 |
| | Haemochromatosis. | Q30251784 |
| | Mouse models of Huntington's disease and methodological considerations for therapeutic trials | Q30481208 |
| | Iron accumulation in the basal ganglia in Huntington's disease: cross-sectional data from the IMAGE-HD study. | Q30946340 |
| | Expression and localization of mitochondrial ferritin mRNA in Alzheimer's disease cerebral cortex | Q31027425 |
| | Selective determination of mitochondrial chelatable iron in viable cells with a new fluorescent sensor | Q31037490 |
| | A simple, highly sensitive and improved method for the measurement of bleomycin-detectable iron: the 'catalytic iron index' and its value in the assessment of iron status in haemochromatosis | Q32061657 |
| | Regional and cellular gene expression changes in human Huntington's disease brain | Q33233457 |
| | Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia | Q33322579 |
| | Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease. | Q33684033 |
| | The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease | Q34011801 |
| | Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in rats. | Q34013010 |
| | Ferroptosis: Death by Lipid Peroxidation | Q34045575 |
| | Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models | Q34408158 |
| | Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity | Q34634421 |
| | Common dysregulation network in the human prefrontal cortex underlies two neurodegenerative diseases | Q34986607 |
| | Iron accumulates in Huntington's disease neurons: protection by deferoxamine | Q35023030 |
| | Neonatal iron supplementation potentiates oxidative stress, energetic dysfunction and neurodegeneration in the R6/2 mouse model of Huntington's disease. | Q35143644 |
| | Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington's disease mice | Q35152150 |
| | Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease | Q35747131 |
| | Disruption of ATP-binding cassette B8 in mice leads to cardiomyopathy through a decrease in mitochondrial iron export | Q35837234 |
| | Alterations in brain transition metals in Huntington disease: an evolving and intricate story | Q36838442 |
| | Quantitative Susceptibility Mapping Suggests Altered Brain Iron in Premanifest Huntington Disease. | Q36902073 |
| | Neonatal Iron Supplementation Induces Striatal Atrophy in Female YAC128 Huntington's Disease Mice | Q36986770 |
| | VCP recruitment to mitochondria causes mitophagy impairment and neurodegeneration in models of Huntington's disease | Q37223339 |
| | Friedreich ataxia: neuropathology revised | Q37278583 |
| | Frequency of nuclear mutant huntingtin inclusion formation in neurons and glia is cell-type-specific. | Q37456579 |
| | Oxidative metabolism and Ca2+ handling in isolated brain mitochondria and striatal neurons from R6/2 mice, a model of Huntington's disease | Q37530288 |
| | Iron-dependent functions of mitochondria--relation to neurodegeneration | Q37821334 |
| | Review: iron metabolism and the role of iron in neurodegenerative disorders | Q38155941 |
| | Cysteine-mediated redox signalling in the mitochondria. | Q38292320 |
| | Reduced Mitochondrial Function in Human Huntington Disease Lymphoblasts is Not Due to Alterations in Cardiolipin Metabolism or Mitochondrial Supercomplex Assembly | Q38410393 |
| | Neurodegenerations with Brain Iron Accumulation | Q38576689 |
| | Impact of high iron intake on cognition and neurodegeneration in humans and in animal models: a systematic review | Q38785723 |
| | Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich's ataxia | Q38821023 |
| | Management of iron overload in hemoglobinopathies. | Q39412094 |
| | Bioenergetic dysfunction in Huntington's disease human cybrids. | Q39522256 |
| | Alterations in the mitochondrial proteome of neuroblastoma cells in response to complex 1 inhibition. | Q39591876 |
| | Neuroprotective mechanism of mitochondrial ferritin on 6-hydroxydopamine-induced dopaminergic cell damage: implication for neuroprotection in Parkinson's disease. | Q39745493 |
| | Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation | Q39939146 |
| | Contribution of aldehyde dehydrogenase to mitochondrial bioactivation of nitroglycerin: evidence for the activation of purified soluble guanylate cyclase through direct formation of nitric oxide. | Q40514133 |
| | Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release | Q40551652 |
| | Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. | Q40721588 |
| | Human frataxin maintains mitochondrial iron homeostasis in Saccharomyces cerevisiae. | Q40849308 |
| | Regulating the fate of mRNA: the control of cellular iron metabolism | Q40851091 |
| | Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis. | Q41187089 |
| | Regional mitochondrial respiratory activity in Huntington's disease brain | Q41360902 |
| | Aceruloplasminemia, an iron metabolic disorder | Q42455448 |
| | Cyclosporine A and MnTMPyP Alleviate α-Synuclein Expression and Aggregation in Cypermethrin-Induced Parkinsonism | Q42703703 |
| | Ring sideroblasts and sideroblastic anemias | Q42743016 |
| | Effects of increased iron intake during the neonatal period on the brain of adult AbetaPP/PS1 transgenic mice. | Q43161323 |
| | Mitochondrial iron and energetic dysfunction distinguish fibroblasts and induced neurons from pantothenate kinase-associated neurodegeneration patients | Q43178831 |
| | Mitochondrial ferritin attenuates β-amyloid-induced neurotoxicity: reduction in oxidative damage through the Erk/P38 mitogen-activated protein kinase pathways | Q43601835 |
| | The iron chelator pyridoxal isonicotinoyl hydrazone inhibits mitochondrial lipid peroxidation induced by Fe(II)-citrate | Q43846361 |
| | Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses | Q44092340 |
| | The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins | Q44092352 |
| | Cypermethrin-induced nigrostriatal dopaminergic neurodegeneration alters the mitochondrial function: a proteomics study | Q44650375 |
| | Iron-sulfur enzyme mediated mitochondrial superoxide toxicity in experimental Parkinson's disease | Q45018861 |
| | Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation | Q45077697 |
| | Abnormal response to cortical activation in early stages of Huntington disease | Q45288459 |
| | Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease | Q45289366 |
| | Mitochondrial defect in Huntington's disease caudate nucleus | Q45291734 |
| | Biochemical abnormalities and excitotoxicity in Huntington's disease brain. | Q45297145 |
| | Neuropathological classification of Huntington's disease | Q45297167 |
| | p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease | Q45297400 |
| | Decreased expression of striatal signaling genes in a mouse model of Huntington's disease | Q45300376 |
| | Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. | Q45302702 |
| | Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease | Q45305307 |
| | Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. | Q45305391 |
| | Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. | Q46306829 |
| | Mitoferrin modulates iron toxicity in a Drosophila model of Friedreich's ataxia. | Q47072104 |
| | Towards an Understanding of Energy Impairment in Huntington's Disease Brain | Q47442924 |
| | Clinical Experience With Deferiprone Treatment for Friedreich Ataxia | Q47786184 |
| | Alpha-synuclein induced membrane depolarization and loss of phosphorylation capacity of isolated rat brain mitochondria: implications in Parkinson's disease | Q48274235 |
| | Huntington disease | Q48465200 |
| | Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. | Q48502457 |
| P921 | main subject | Huntington's disease | Q190564 |
| P304 | page(s) | 317-329 | |
| P577 | publication date | 2018-04-04 | |
| P1433 | published in | Free Radical Biology and Medicine | Q5500023 |
| P1476 | title | Brain mitochondrial iron accumulates in Huntington's disease, mediates mitochondrial dysfunction, and can be removed pharmacologically | |
| P478 | volume | 120 | |